Intraocular inflammation following aflibercept 8 mg: real-world data from a multicentre retrospective observational study
Lea-Noelle Stoehr, Philip Wakili, Warda Darwisch, Franziska Seufert, Robert P Finger, Peter Szurman, Boris V Stanzel · 2025
Read Intraocular inflammation following aflibercept 8 mg: real-world data from a multicentre retrospective observational study by Lea-Noelle Stoehr, Philip Wakili, Warda Darwisch, Franziska Seufert, Robert P Finger, Peter Szurman, Boris V Stanzel (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12781524.txt.
Description
Lea-Noelle Stoehr and co-authors report eye inflammation after injections of a stronger eye drug dose in a 2025 study. The drug, aflibercept at eight milligrams, treats wet macular degeneration and diabetic eye swelling. Reports of sterile inflammation inside the eye after this dose were scarce. Three centers logged twelve eyes with such inflammation between mid-2024 and mid-2025.
The inflammation struck about two days after injection, on average after the second or third dose. Most patients had been treated before with no such event, many with the older two-milligram dose. The middle layer of the eye was hit in two-thirds of cases. The rate worked out to about 1.4 percent per injection at the three centers. The series helps clinics weigh the higher dose.
Catalog record
| CREATOR | Lea-Noelle Stoehr, Philip Wakili, Warda Darwisch, Franziska Seufert, Robert P Finger, Peter Szurman, Boris V Stanzel |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |